NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: The role of dosimetric and clinical factors  by Beetz, Ivo et al.
Radiotherapy and Oncology 105 (2012) 101–106Contents lists available at SciVerse ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .comALLEGRO project
NTCP models for patient-rated xerostomia and sticky saliva after treatment
with intensity modulated radiotherapy for head and neck cancer: The role
of dosimetric and clinical factorsq
Ivo Beetz a,⇑, Cornelis Schilstra a, Arjen van der Schaaf a, Edwin R. van den Heuvel b, Patricia Doornaert c,
Peter van Luijk a, Arjan Vissink d, Bernard F.A.M. van der Laan e, Charles R. Leemans f, Henk P. Bijl a,
Miranda E.M.C. Christianen a, Roel J.H.M. Steenbakkers a, Johannes A. Langendijk a
aDepartment of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; bDepartment of Epidemiology,
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; cDepartment of Radiation Oncology, VU University Medical Center (VUMC), Amsterdam,
The Netherlands; dDepartment of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;
eDepartment of Otolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
fDepartment of Otolaryngology-Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
a r t i c l e i n f oArticle history:
Received 29 December 2011
Received in revised form 18 February 2012
Accepted 10 March 2012
Available online 18 April 2012
Keywords:
Head and neck cancer
NTCP modeling
Patient-rated xerostomia
IMRT0167-8140  2012 Elsevier Ireland Ltd.
http://dx.doi.org/10.1016/j.radonc.2012.03.004
q This study was supported by a grant of the Europe
⇑ Corresponding author. Address: Department of Ra
of Groningen, University Medical Center Groningen
Groningen, The Netherlands.
E-mail address: i.beetz@umcg.nl (I. Beetz).
Open access unda b s t r a c t
Purpose: The purpose of this multicentre prospective study was to develop multivariable logistic regres-
sion models to make valid predictions about the risk of moderate-to-severe patient-rated xerostomia
(XERM6) and sticky saliva 6 months (STICM6) after primary treatment with intensity modulated radiother-
apy (IMRT) with or without chemotherapy for head and neck cancer (HNC).
Methods and materials: The study population was composed of 178 consecutive HNC patients treated
with IMRT. All patients were included in a standard follow up programme in which acute and late side
effects and quality of life were prospectively assessed, prior to, during and after treatment.
The primary endpoints were XERM6 and STICM6 as assessed by the EORTC QLQ-H&N35 after completing
IMRT. Organs at risk (OARs) potentially involved in salivary function were delineated on planning-CT,
including the parotid, submandibular and sublingual glands and the minor glands in the soft palate,
cheeks and lips. Patients with moderate-to-severe xerostomia or sticky saliva, respectively, at baseline
were excluded.
The optimal number of variables for a multivariate logistic regression model was determined using a
bootstrapping method.
Results: Eventually, 51.6% of the cases suffered from XERM6. The multivariate analysis showed that the
mean contralateral parotid gland dose and baseline xerostomia (none vs. a bit) were the most important
predictors for XERM6. For the multivariate NTCP model, the area under the receiver operating curve (AUC)
was 0.68 (95% CI 0.60–0.76) and the discrimination slope was 0.10, respectively. Calibration was good
with a calibration slope of 1.0.
At 6 months after IMRT, 35.6% of the cases reported STICM6. The mean contralateral submandibular gland
dose, the mean sublingual dose and the mean dose to the minor salivary glands located in the soft palate
were most predictive for STICM6. For this model, the AUC was 0.70 (95% CI 0.61–0.78) and the discrimi-
nation slope was 0.12. Calibration was good with a calibration slope of 1.0.
Conclusions: The multivariable NTCP models presented in this paper can be used to predict patient-rated
xerostomia and sticky saliva. The dose volume parameters included in the models can be used to further
optimise IMRT treatment.
 2012 Elsevier Ireland Ltd.Open access under the Elsevier OA license.
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in the head and neck region is hyposalivation and subsequentan Union (ALLEGRO-project).
diation Oncology, University
, P.O. Box 30001, 9700 RB
er the Elsevier OA license.xerostomia, resulting from irradiation of at least some parts of
the salivary glands [1–8].
The current study, including head and neck cancer (HNC) pa-
tients treated with curatively intended radiotherapy (RT) or che-
moradiation (CHRT), was part of the ALLEGRO project (EArLy and
Late hEalth risks to normal/healthy tissues from the use of existing
and emerGing techniques for RadiatiOn therapy), funded by the
European Union [9]. One of the objectives of this project was to
102 Multivariate NTCP models for head and neck cancer patients treated with IMRTdevelop multivariable Normal Tissue Complication Probability
(NTCP) models for patients treated with 3D conformal radiother-
apy (3D-CRT) and to investigate if these models were sufﬁciently
valid when used among patients treated with new and emerging
radiation techniques, such as with intensity modulated radiother-
apy (IMRT).
Recently, we reported on the results of a prospective study,
which was conducted to develop multivariable NTCP models for
patient-rated moderate-to-severe xerostomia and sticky saliva
among head and neck cancer (HNC) patients treated with 3D-CRT
[10]. In a subsequent analysis, we tested the validity of these 3D-
CRT based NTCP-models among patients treated with IMRT [11].
The results of that study showed that the 3D-CRT based NTCP mod-
els performed worse among patients treated with IMRT, suggesting
that major changes in dose distributions in relevant organs at risk
(OAR), in particular in the salivary glands, may hamper the perfor-
mance of 3D-CRT based NTCP-models.
This raises the question if multivariable models initially devel-
oped among patients treated with IMRT will indeed be different
from the 3D-CRT based models and, ultimately, will do better in
terms of predictive power and model performance.
Therefore, the ﬁrst objective of the current study was to develop
multivariable NTCP models for patient-rated xerostomia and sticky
saliva among patients treated with IMRT. The second objective was
to test if these models indeed performed better than the 3D-CRT
based multivariable NTCP models as reported in earlier studies.
Methods and materials
Patients
To be included in the analysis, patients had to fulﬁl the follow-
ing eligibility criteria: (1) HNC originating in the oral cavity, oro-
pharynx, larynx, hypopharynx, nasopharynx, paranasal sinuses or
cervical lymph node metastases from unknown primary tumours;
(2) treated with deﬁnitive IMRT either alone or in combination
with chemotherapy or cetuximab; (3) no previous surgery, radio-
therapy and/or chemotherapy ((CH)RT); (4) no previous malignan-
cies; (5) no distant metastases, and: (6) health related quality of
life (HRQoL) assessments available prior to and at 6 months after
completion of RT or CHRT. The study was conducted according to
the regular procedures of the local ethical committee of the Uni-
versity Medical Centre Groningen and VU University Medical Cen-
tre, Amsterdam.
The standardised follow up programme
All patients included in this analysis were subjected to a stan-
dard follow-up programme as previously described [10,12]. In
summary this programme includes a prospective evaluation of tox-
icity and quality of life on a routine basis, prior to, during and at
regular intervals, weekly during treatment, 6 weeks and every
6 months up to 60 months after curative RT or CHRT.
Endpoints
For the evaluation of patient-rated xerostomia and sticky saliva,
the EORTC QLQ-H&N35 questionnaire was used prior to and
6 months after treatment. For all questions, including those regard-
ing xerostomia and sticky saliva, a 4-point Likert scale was used
ranging from none, a bit, quite a bit, to a lot. For the purpose of this
study, the primary endpoint was deﬁned as moderate-to-severe
xerostomia at 6 months (XERM6) and sticky saliva (STICM6) after
completion of radiotherapy, which corresponds with the two high-
est scores on the 4-point scale. Patients with moderate-to-severe
xerostomia or sticky saliva at baseline, respectively, were excluded
from the analysis. This was done, as we were primarily interestedin xerostomia and sticky saliva induced by radiation treatment
itself.Treatment
In all patients, a planning CT-scan with contrast-enhancement
was performed in treatment position. Radiotherapy was delivered
using a 6 MV linear accelerator. The target volumes for the initial
ﬁelds and boosts were similar as reported in earlier studies [10].
In summary, the clinical target volume of the initial ﬁeld (CTV1)
was composed of the primary tumour and pathological lymph
nodes plus a 1.0 cm margin, and the elective nodal areas on both
sides of the neck, selected according to the guidelines reported
by Gregoire et al. [13]. The CTV for the boost irradiation (CTV2)
consisted of the primary tumour and pathological lymph nodes
with a 0.5 cm margin. In all cases, a 0.5 cm margin was applied
for the planning target volumes (PTV1 and PTV2). The mean dose
to both parotid glands was reduced as much as possible without
compromising the required dose to the target volumes.
Patients were treated with dynamic IMRT with a sliding win-
dow technique, as well as with step-and-shoot IMRT. In general,
a seven-ﬁeld equidistant, non-opposing beam conﬁguration was
used. Step-and-shoot IMRT treatment planning was performed
on the Pinnacle Treatment Planning System (TPS) (version 8.0 h,
Philips Radiation Oncology Systems, Fitchburg, WI). Dynamic IMRT
treatment planning was performed on Eclipse (version 7.1.31, Var-
ian Medical Systems Inc., USA). All patients were treated with a
simultaneous integrated boost (SIB) technique. PTV1 was treated
with 35 fractions of 1.55 Gy up to a total dose of 54.25 Gy. The
PTV2 was treated with 35 fractions of 2 Gy up to a total dose of
70 Gy.Contouring of organs at risk
OARs potentially involved in salivary function related symp-
toms were delineated according to the guidelines as described by
van de Water et al. [14]. These included the parotid, submandibu-
lar and sublingual glands, as well as the minor salivary glands lo-
cated in the soft palate, the inner surface of the lower and upper
lips and the minor salivary glands in the inner surface of the
cheeks. All OARs were delineated by an expert in head and neck
radiation oncology.Statistics
NTCP models for moderate-to-severe patient-rated xerostomia
and sticky saliva were developed using a multivariable logistic
regression analysis with an extended bootstrapping technique
and forward variable selection as previously described [10]. The
model with the highest average likelihood was selected as the best
predictive model.
Before carrying out the regression analysis, a correlation matrix
was produced to check for high correlations between candidate
prognostic determinants, in particular between dose volume histo-
gram (DVH) parameters. In case of Pearson correlation coefﬁcients
P0.75 between candidate prognostic determinants, these vari-
ables were combined into a single variable to avoid the problem
of multicollinearity which may negatively affect the generalisabil-
ity of the model. Finally, all DVH data were connected to all other
potential pre-treatment prognostic factors for each individual
patient.
After reducing the number of variables based on the correlation
coefﬁcient analysis, a multivariable logistic regression analysis
with forward selection and an extended bootstrapping technique
was carried out. We used 2000 bootstraps for each analysis. For
every model order, the average likelihood of predictions was
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average likelihood was selected for the deﬁnite NTCP model for
moderate-to-severe patient-rated xerostomia and sticky saliva.
After selecting the combination of variables with the highest
performance, adjusted Odd’s ratios (OR) and 95% conﬁdence inter-
vals (95% CI) were calculated for the selected variables in the mod-
el. For each patient, predictive values were calculated for each set
of prognostic variables based on the regression coefﬁcients accord-
ing to the formula:
NTCP ¼ ð1þ eSÞ1; whereS ¼ b0 þ
Pn
i¼1
bi  xi:
Model performance was described using different validation
tools [15,16]. The overall performance was expressed by Nage-
lkerke’s R2, which quantiﬁes the amount of explained variation
by the model [17]. In addition, model performance was evaluated
using measures for discriminative ability, including the Area Under
the receiver operating Curve (AUC) [18,19] and by calculating the
discrimination slope, deﬁned as the absolute difference between
the mean predicted NTCP-values of patients with the primary end-
point and those without. Model performance was further quanti-
ﬁed in terms of calibration, i.e. the agreement between predicted
and observed outcome in the dataset, while the Hosmer–Leme-
show ‘‘goodness-of-ﬁt’’ test [20] was used to test the agreement
between the expected and observed outcomes.Results
The majority of patients were male (71%) and the median age of
the study population was 61.0 years, ranging from 32 to 85 years
for patients included in both the xerostomia and sticky saliva anal-
ysis. One third of the patients were treated with IMRT in combina-
tion with chemotherapy (33%). The demographic and tumour
characteristics of the study population are listed in Table 1.
From the 178 patients treated with IMRT, 17 already suffered
from moderate-to-severe xerostomia at baseline and wereTable 1
Demographic and disease-related characteristics for the patients included in the xerostom
Characteristics Xerostomia
Sex Male 114
Female 47
Age <65 113
>65 48
Chemotherapy Yes 53
No 108
Cetuximab Yes 10
No 151
Tumour classiﬁcation T0 6
T1 13
T2 50
T3 51
T4 41
Node classiﬁcation Positive 99
Negative 62
Site Oral cavity 57
Oropharynx 12
Larynx 59
Hypopharynx 20
Nasopharynx 1
Sinuses 8
Unknown primary 4
Bilateral neck irradiation Yes 139
No 22excluded from further analysis, leaving 161 patients to be ana-
lysed. Twenty-three patients suffered from moderate-to-severe
sticky saliva and were excluded from the analysis for STICm6. Out
of the remaining 156 patients for the analysis of sticky saliva,
149 (96%) completed the EORTC QLQ-HN35 at 6 months after
treatment and were included in the analysis.
To reduce the number of variables eventually included in the
analysis a correlation matrix was produced. For all OARs, high cor-
relations were found between all DVH-parameters and the mean
dose of that OAR. Therefore, we excluded the VX values which were
highly correlated with each other from the analysis. High correla-
tions were also found between the mean dose to the upper and
lower lips, the mean dose to the left and right cheeks and the mean
dose to the sublingual glands and, therefore, we decided to include
the mean doses of these paired glands as one single variable each
in the analysis. Eventually, eight DVH parameters were included
in the analysis (Supplement 1).
Six months after treatment, 83 patients (51.6 %) suffered from
XERm6. In the univariate analysis, the mean dose in the ipsilateral
and contralateral parotid gland, the mean dose in the ipsilateral
and contralateral submandibular gland, the mean dose in the soft
palate, chemotherapy and baseline xerostomia score (none vs. a
bit) were signiﬁcantly associated with XERM6 after treatment (Sup-
plement 1).
The average likelihood of bootstrap predictions in the multivar-
iable logistic regression analysis was optimal with a model consist-
ing of two variables, including the mean dose in the contralateral
parotid gland and baseline xerostomia (none vs. a bit). The ﬁnal re-
sults of the multivariable logistic regression analysis are listed in
Table 2. The NTCP-curves for the mean contralateral parotid dose
stratiﬁed by baseline xerostomia (none vs. a bit) are depicted in
Fig. 1A. The NTCP-value for each individual patient can be calcu-
lated by the following logistic regression formula:
NTCP ¼ ð1þ eSÞ1; where
S ¼ 1:443þ ðmean dose contralateral parotid gland  0:047Þ
þ ðbaseline xerostomia score  0:720Þia (161) and sticky saliva analysis (n = 149).
(n = 161) % Sticky saliva (n = 149) %
71 106 71
29 43 29
70 102 69
30 47 31
33 49 33
67 100 67
6 8 5
94 141 95
4 6 4
8 13 9
31 47 31
32 46 31
25 37 25
61 83 56
39 65 44
35 50 34
7 11 7
37 55 37
12 20 13
1 1 1
5 8 5
3 4 3
86 129 87
14 20 13
Table 2
Logistic regression coefﬁcients and odds ratios for the NTCP models for patient-rated xerostomia and for patient-rated sticky saliva 6 months after treatment. The constant refers
to the constant of the logistic regression formula.
NTCP model Variable b p-value Odds ratio 95% CI
Patient-rated xerostomia Mean dose contralateral parotid gland (Gy) 0.047 <0.01 1.05 1.02–1.08
Baseline xerostomia score (none vs. a bit) 0.720 0.05 2.05 1.00–4.23
Constant 1.443 <0.01
Patient-rated sticky saliva Mean dose contralateral submandibular gland (Gy) 0.075 <0.01 1.08 1.03–1.13
Mean dose sublingual glands (Gy) 0.060 0.01 0.94 0.90–0.98
Mean dose soft palate (Gy) 0.026 0.04 1.03 1.00–1.05
Constant 3.243 <0.01
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Fig. 1. The NTCP curves for patient-rated xerostomia 6 months after treatment with primary RT or CHRT (A). The lines represent the NTCP curves for patients with no
xerostomia at baseline (red line) and patients with minor xerostomia at baseline (orange line). (B) The NTCP curves for patient-rated sticky saliva 6 months after treatment.
The orange curve represents the situation when the mean dose to the soft palate and sublingual glands equals the mean dose of the study population. The black and red NTCP
curves represent the most extreme values to the soft palate and sublingual glands as observed in the study population. The green dots represent the mean observed risk of
groups of patients. The black dots represent the same group of patients as the green dots, but represent the calculated predicted risk based on the NTCP models.
104 Multivariate NTCP models for head and neck cancer patients treated with IMRTOverall model performance and calibration were satisfactory (Ta-
ble 3). The AUC was 0.68 (95% CI 0.60–0.76) and the discrimination
slope was 0.10, respectively (Table 3). The calibration slope of 1.0
(Fig. 2), indicated a good agreement between observed and pre-
dicted NTCP-values.
Fifty-three patients (35.6%) reported STICM6 after completion of
treatment. In the univariate analysis, the mean dose to the contra-
lateral parotid gland and in the contralateral submandibular glandTable 3
Model performance and internal validation for the NTCP models for patient-rated xerosto
Performance measure
Overall Brier (scaled)
R2 Nagelkerke
Discrimination Area under the curve
Discrimination slope
Calibration Hosmer–Lemeshow test
Intercept of calibration curve
Slope of calibration curvewas signiﬁcantly associated with STICM6 after treatment (Supple-
ment 1).
Average likelihood of bootstrap predictions in the multivariate
logistic regression analysis was optimal with a model consisting
of three variables, including the mean dose in the contralateral
submandibular gland, the mean dose in the sublingual glands,
and the mean dose in the soft palate (Table 2). Of notice is that a
negative regression coefﬁcient was found for the mean dose tomia and sticky saliva.
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Fig. 2. Calibration of the NTCP models for patient-rated xerostomia (A) and calibration (the agreement between predicted and observed outcome) of the NTCP model for
patient-rated sticky saliva (B). All plots show the relation between predicted risk and real outcome. The dots represent groups of patients with a speciﬁc mean calculated
probability. The corrected NTCP is the trendline between the data points compared with the reference line, which indicates a perfect calibration between predicted risk and
real outcome.
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the mean dose to the sublingual glands and the probability on
STICM6. The NTCP-curves for STICM6 as a function of the mean con-
tralateral submandibular dose stratiﬁed by different mean doses in
the sublingual glands and soft palate are depicted in Fig. 1B.
The NTCP-value for each individual patient can be calculated by
the following logistic regression formula:
NTCP ¼ ð1þ eSÞ1; where
S ¼ 3:243þ ðmean dose contralateral submandibular gland
 0:075Þ þ ðmean dose sublingual glands  0:060Þ
þ ðmean dose soft palate  0:026Þ
Overall model performance and calibration were satisfactory (Ta-
ble 3). The discriminative abilities described with the AUC and the
discrimination slope were 0.70 (95% CI 0.61–0.78) and 0.12, respec-
tively (Table 3). Calibration, the agreement between predictive risk
and the observed outcome was good with a calibration slope of 1.0
(Fig. 2).Discussion
In this study, we developed predictive models for XERM6 and
STICM6 for HNC patients treated with primary RT or CHRT using
IMRT. The analysis showed that the contralateral parotid gland
was the most important OAR for XERM6. For STICm6, the contralat-
eral submandibular gland, the sublingual glands and the minor
glands in the soft palate turned out to be the most important OARs.
In a previous report, we showed that the performance of 3D-
CRT based multivariable predictive models for XERM6 and STICM6
were markedly worse when used among patients treated with
IMRT [11]. In particular, there was a signiﬁcant discrepancy be-
tween predicted and observed outcome values (calibration). Based
on these results the current analysis was performed in order to see
if we could develop separate multivariable NTCP models for the
same endpoints among patients treated with IMRT with better per-
formance than the 3D-CRT based models.
In the current analysis, the two-factor model containing base-
line xerostomia and the mean dose to the contralateral gland per-
formed signiﬁcantly better in that respect. Overall performance as
described with the scaled Brier score and explained variance in-
creased respectively from 0.04 to 0.10 and from 0.05 to 0.13. Cali-
bration, the differences between observed and predicted risk, was
markedly better (increased from 0.53 to 1.0) and the Hosmer–
Lemeshow test did not show a signiﬁcant disagreement betweenpredicted and observed risk anymore. The question arises as to
whether there is a logical explanation for the differences found be-
tween the 3D-CRT based NTCP models and the IMRT-based NTCP
models.
First, it should be noted that patient-rated xerostomia is a
rather complex endpoint, which can be inﬂuenced by several fac-
tors either related to dose distributions to major and minor sali-
vary glands, or by other factors such as baseline xerostomia, age
and medication [10,21–24]. Although we tried to take these factors
into account as much as possible, given the relatively low values
for the explained variance of the model, there will be other prog-
nostic factors that remained unidentiﬁed.
Second, signiﬁcant differences were noted with regard to the
dose distributions to particularly the parotid glands. In the 3D-
CRT cohort, the average mean dose to the ipsilateral and contralat-
eral parotid glands was highly correlated, while in the IMRT cohort
this correlation was much weaker, allowing the ipsilateral and con-
tralateral parotid glands to be entered in the multivariable model
as two separate OARs. As the average mean dose to the contralat-
eral parotid glands was signiﬁcantly lower when treated with
IMRT, it is not surprising that the mean dose to the contralateral
parotid gland turned out to be more important than the dose to
the ipsilateral gland. Indeed, some investigators showed that the
contralateral parotid ﬂow increased after unilateral irradiation
[25–27]. These investigators showed that when patients were trea-
ted with unilateral irradiation, the stimulated and unstimulated
salivary production was taken over by the spared contralateral par-
otid gland and that physician-rated toxicity was particularly corre-
lated with the radiation dose to these spared parotid glands
[25,27].
In the current analysis, the three-factor model for STICM6 per-
formed with regard to overall performance and calibration signiﬁ-
cantly better than the four factor 3D-CRTmodel which contains the
submandibular, sublingual glands, baseline sticky saliva and age
[10].
The submandibular glands and sublingual glands play a pivotal
role in the development of sticky saliva, for patients treated with
IMRT as well for those treated with 3D-CRT. A remarkable ﬁnding
was the inverse relationship between the mean dose to the sublin-
gual glands and patient-rated sticky saliva. Irradiation of the sub-
mandibular glands and parotid glands reduce the production of
serous saliva. Sparing of the sublingual glands, which are responsi-
ble for more mucous secretion of saliva, will change the ratio be-
tween mucous and serous saliva, resulting in a higher viscosity
of the produced saliva [28]. Irradiation to the sublingual glands will
reduce the mucous saliva production resulting in a more balanced
ratio between mucous and serous saliva production.
106 Multivariate NTCP models for head and neck cancer patients treated with IMRTGiven that the risk on the endpoints discussed depends on more
than one factor, it is not possible to deﬁne clear dose constraints as
the threshold dose for the DVH parameters which were identiﬁed
will be different in the various subsets. E.g. for patient-rated xero-
stomia, the dose response curves for patients with and without
baseline xerostomia will be different. For sticky saliva, this will
be even more difﬁcult as the risk on patient-rated sticky saliva de-
pend on even more factors.
In the current analysis, the mean dose to the soft palate had a
minor though signiﬁcant effect on the development of STICM6. Such
relationship was not found in the 3D-CRT cohort. IMRT primarily
aiming at sparing the parotid glands, will inevitably result in addi-
tional different dose distributions to other regions, such as the oral
cavity, which may result in different dose distributions to the min-
or salivary glands, such as those located in the soft palate. Indeed,
in our study populations, in patients treated with IMRT, the aver-
age mean dose to the soft palate was 15 Gy higher as compared
to that in patients treated with 3D-CRT (data not shown). Possibly,
these higher doses exceed the threshold dose of the minor salivary
glands located in the soft palate, which may explain the increasing
importance of the mean dose to the soft palate. Also other authors
found that the minor salivary glands are important for symptoms
related to salivary function as reported by patients. Little et al.
showed a shifting importance of dose distributions to the minor
salivary glands located in the oral cavity when the parotid and sub-
mandibular glands were spared with IMRT with regard to patient-
rated xerostomia [29].
In conclusion we developed predictive models which are valid
for patients treated with IMRT. These models are useful to further
optimise current IMRT treatment with regard to patient rated
xerostomia and sticky saliva and are more reliable to predict these
endpoints when patients will be treated with IMRT and indicate
which organs at risk are the most important to spare as much as
possible, to optimise current treatment with IMRT.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2012.03.
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